Vitamin price-fixing settlement
This article was originally published in The Tan Sheet
Executive Summary
Jan. 15 hearing scheduled in D.C. federal court on fairness of proposed $50 mil. settlement by Merck KgaA and its affiliates of class action claims brought by direct purchasers of vitamins A, B, C, E, beta carotene, premixes. Judge Thomas Hogan preliminarily approved the settlement in September; opt-out deadline for companies who wish to exclude themselves is Dec. 9. Unlike earlier settlement involving seven defendants including Hoffman-LaRoche and BASF, Merck settlement amount is fixed and will not be reduced by the number of class members opting out. Remaining defendants in the class action, which is scheduled for trial March 12, include Sumitomo Chemical America, Tanabe USA, Lonza, Degussa-Huls, Reilly Industries, Nepera (1"The Tan Sheet" March 4, 2002, p. 11)...
You may also be interested in...
Vitamin price-fixing
Dietary supplement manufacturer and multi-level marketer Shaklee is one of eight representative plaintiffs in class action suit certified by D.C. federal Judge Thomas Hogan Feb. 25. Action was filed in June 2000 on behalf of direct purchasers of vitamins A, B, C, E, beta carotene and premixes from nonsettling defendants "or their co-conspirators" between Jan. 1, 1990 and Sept. 30, 1998. Defendants include Merck KgaA, Sumitomo Chemical America, Tanabe USA, Lonza, Nepera, Reilly Industries, Degussa-Huls. The thousands of class members will be given chance to opt out; 224 class members, representing approximately 75% of vitamin purchases at issue, previously opted out of a class settlement against seven defendants, including Hoffman-LaRoche, BASF (1"The Tan Sheet" April 3, 2000, p. 7)...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.